PRPO 📈 Precipio - Overview
Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US74019L5030
PRPO: Diagnostic Testing, Cell Culture Media, Genetic Panels, Biomarkers
Precipio, Inc., a healthcare solutions company, provides diagnostic products, reagents, and services in the United States. It provides diagnostic blood cancer testing services. The company offers IV-Cell, a proprietary cell culture media that enables simultaneous culturing of four hematopoietic cell lineages; and HemeScreen, a suite of robust genetic diagnostic panels. It offers biomarker testing and clinical project services to bio-pharma customers. The company is based in New Haven, Connecticut. Web URL: https://www.precipiodx.com
Additional Sources for PRPO Stock
News:
Wall Street Journal
Benzinga
Yahoo Finance
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
PRPO Stock Overview
| Market Cap in USD | 9m |
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| GiC Sub-Industry | Health Care Services |
| IPO / Inception | 2000-07-18 |
PRPO Stock Ratings
| Growth 5y | -78.2% |
| Fundamental | -28.3% |
| Dividend | - |
| Rel. Strength Industry | -870 |
| Analysts | 5/5 |
| Fair Price Momentum | 3.70 USD |
| Fair Price DCF | - |
PRPO Dividends
No Dividends PaidPRPO Growth Ratios
| Growth Correlation 3m | -92.3% |
| Growth Correlation 12m | -13.8% |
| Growth Correlation 5y | -81.5% |
| CAGR 5y | -33.33% |
| CAGR/Mean DD 5y | -0.43 |
| Sharpe Ratio 12m | -0.14 |
| Alpha | -45.51 |
| Beta | 1.03 |
| Volatility | 70.61% |
| Current Volume | 2.6k |
| Average Volume 20d | 5.8k |
What is the price of PRPO stocks?
As of December 21, 2024, the stock is trading at USD 5.27 with a total of 2,600 shares traded.
Over the past week, the price has changed by -14.26%, over one month by -12.87%, over three months by -14.65% and over the past year by -17.94%.
As of December 21, 2024, the stock is trading at USD 5.27 with a total of 2,600 shares traded.
Over the past week, the price has changed by -14.26%, over one month by -12.87%, over three months by -14.65% and over the past year by -17.94%.
Is Precipio a good stock to buy?
Probably not. Based on ValueRay Fundamental Analyses, Precipio (NASDAQ:PRPO) is currently (December 2024) not a good stock to buy. It has a ValueRay Fundamental Rating of -28.26 and therefor a somewhat negative outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of PRPO as of December 2024 is 3.70. This means that PRPO is currently overvalued and has a potential downside of -29.79%.
Probably not. Based on ValueRay Fundamental Analyses, Precipio (NASDAQ:PRPO) is currently (December 2024) not a good stock to buy. It has a ValueRay Fundamental Rating of -28.26 and therefor a somewhat negative outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of PRPO as of December 2024 is 3.70. This means that PRPO is currently overvalued and has a potential downside of -29.79%.
Is PRPO a buy, sell or hold?
Precipio has received a consensus analysts rating of 5.00. Therefor, it is recommend to buy PRPO.
Precipio has received a consensus analysts rating of 5.00. Therefor, it is recommend to buy PRPO.
- Strong Buy: 1
- Buy: 0
- Hold: 0
- Sell: 0
- Strong Sell: 0
What are the forecast for PRPO stock price target?
According to ValueRays Forecast Model, PRPO Precipio will be worth about 4.1 in December 2025. The stock is currently trading at 5.27. This means that the stock has a potential downside of -22.2%.
According to ValueRays Forecast Model, PRPO Precipio will be worth about 4.1 in December 2025. The stock is currently trading at 5.27. This means that the stock has a potential downside of -22.2%.
| Issuer | Forecast | Upside |
|---|---|---|
| Wallstreet Target Price | 19 | 260.5% |
| Analysts Target Price | 40 | 659% |
| ValueRay Target Price | 4.1 | -22.2% |